What does EGFR mutation prevalence look like in early-stage resectable NSCLC in Spain when you base it on routine surgical cases? The ORIGEN study explores this question, and APICES was acknowledged for supporting multiple study activities.
We want to share the acknowledgment that APICES has received in ORIGEN study, which is an NSCLC retrospective study, published in the ESMO 2023 congress, in which APICES has collaborated instart-up, project management, monitoring, biostatistics, and medical writing activities.
This recognition is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. APICES is very proud of the acknowledgment of our work, and we would like to thank the authors and Astrazeneca, for giving us the opportunity to appear in the acknowledgments of the publication. We also congratulate them and all the investigators on the success of their project.
This Retrospective study aims to determine the prevalence of sensitizing EGFR mutations using real-time PCR-based molecular analysis in patients with early-stage nonsquamous NSCLC with stage IA–IIIB disease, who underwent surgical resection in Spain.
On integration, change leadership, and strengthening Apices as one unified organization In a clinical research environment where sponsors value stability, predictability, and quality above all else, organizational change must be approached with care. As APICES...
RWE and HEOR have moved from supporting inputs to decision-critical evidence across development and access. This article summarises what teams are using them for today, how evidence generation is changing, and where AI adds value when paired with the right governance.
Stage III NSCLC care sits at the intersection of multimodal treatment and real-world constraints. The GEOCP-SEOR population-based study describes how patients are managed across Spain, and APICES was acknowledged for supporting the publication through medical editorial assistance.